Year: 2026
Type: review
Abstract: Prior meta-analysis has suggested a progression-free survival (PFS) advantage for anti-PD1 agents plus chemotherapy (CT) vs anti-PD-L1+CT (excluding PARP inhibitors) in treatment of patients with 1L pMMR primary advanced or recurrent endometrial cancer. In the NRG-GY018 trial (pembrolizumab (PEM)+CT vs. CT), 43% of control patients in the pMMR cohort switched to PEM arm before progression after achieving successful PFS (primary hypothesis) at interim analysis, confounding the subsequent PFS measures.
Source: ESMO Open
Authors: C. Marth, R. Paranjpe, O. Egunsola, A. Fredrickson, V. Prabhu, R. Massaad, P. Jelinic
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167065558
FWCI:
Cites:
Cited by:
Related to: